Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus PIPRACIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus PIPRACIL.
LAROTID vs PIPRACIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), interfering with peptidoglycan cross-linking during cell wall assembly.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
3.375 g IV every 6 hours (piperacillin 3 g + tazobactam 0.375 g) over 30 minutes; for nosocomial pneumonia: 4.5 g IV every 6 hours over 30 minutes.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.7-1.2 hours in adults with normal renal function; prolonged to 3-6 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-4 hours.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Primarily renal (tubular secretion and glomerular filtration) as unchanged drug (50-70%); biliary/fecal excretion is a minor route (approximately 10-20% as unchanged drug and metabolites).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic